#CRISPR

3개의 글

July 6, 2026

BEAM (Beam Therapeutics) Stock Outlook 2026: The Next Generation of Base-Editing Gene Therapy

BEAM Beam Therapeutics stock outlook 2026. Base editing technology moat, BEAM-101 sickle cell and beta-thalassemia pipeline, CRSP and NTLA competition, clinical binary risk, cash runway, and a practical positioning framework for investors.

BEAM Beam Therapeutics base editing

2026년 7월 6일

BEAM 빔테라퓨틱스 주가 전망 2026: 염기교정 유전자치료의 다음 세대

BEAM 빔테라퓨틱스 주가 전망 2026년. 염기교정(base editing) 기술 해자, BEAM-101 겸상적혈구·베타지중해빈혈 파이프라인, CRSP·NTLA 경쟁 비교, 임상 바이너리 리스크와 현금 러너웨이, 한국 투자자 실전 시나리오 3가지를 정리했습니다.

BEAM 빔테라퓨틱스 염기교정

June 30, 2026

NTLA Stock Outlook 2026: In-Vivo CRISPR's Clinical Crossroads

Intellia Therapeutics (NTLA) 2026 investment analysis: in-vivo CRISPR gene editing differentiation, the NTLA-2001 ATTR amyloidosis and NTLA-2002 hereditary angioedema late-stage trials, cash burn and dilution, regulatory and safety risk, plus bull and bear scenarios for investors.

NTLA Intellia US Stocks